Drug and Alcohol Rehabilitation: [Analysis of the Epidemiological Characteristics of Hepatitis E and Genotypes of Hepatitis E Virus Among Drug Users].
[Analysis of the epidemiological characteristics of hepatitis E and genotypes of hepatitis E virus among drug users].
Filed under: Drug and Alcohol Rehabilitation
Zhonghua Liu Xing Bing Xue Za Zhi. 2012 Mar; 33(3): 347-8
Wen YF, Cheng XF, Xiang KX, Zhu M
Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis.
Filed under: Drug and Alcohol Rehabilitation
Allergy Asthma Proc. 2012 May-Jun; 33(3): 265-74
Meier EJ, Torkildsen GL, Gow JA, McNamara TR, Gomes PJ, Williams JI,
Allergic conjunctivitis is a clinical reaction to environmental allergens and is manifested by ocular itching caused by IgE-induced mast cell degranulation. Bepotastine besilate is a selective H(1)-antagonist with mast cell stabilizing properties. This report examines the reduction of ocular itching integrated from two conjunctival allergen challenge (CAC) clinical trials comparing bepotastine besilate ophthalmic solution (BBOS) 1.5% to placebo in subjects with a history of allergic conjunctivitis. Two phase III, double-masked, placebo-controlled, parallel-group, CAC clinical trials evaluated BBOS 1.5% versus placebo to reduce ocular itching. Eligible subjects were randomly assigned 1:1 to either BBOS 1.5% (n = 78) or placebo (n = 79). Ocular itching was graded by subjects using a standardized scale (0–4 U). Adverse events and ophthalmic clinical findings were recorded for safety. BBOS 1.5% was superior to placebo for reducing CAC-induced ocular itching (p < 0.0001) as early as 3 minutes post-CAC and for at least 8 hours after dosing. Post hoc analyses examining several populations also showed a significant improvement (p < 0.0001) for subjects with more severe itching response at screening and for the proportion of subjects with complete or nearly complete resolution of CAC-induced itching, both outcomes supporting the clinical benefit of BBOS 1.5%. Adverse events were generally transient and mild. BBOS 1.5% is safe and effective in the treatment of ocular itching associated with allergic conjunctivitis within 3 minutes of a CAC and with a sustained duration of action of at least 8 hours. (ClinicalTrials.gov numbers: NCT00424398 and NCT00586664). HubMed – drug
Rapid determination and comparative pharmacokinetics of tetrahydropalmatine in spontaneously hypertensive rats and normotensive rats.
Filed under: Drug and Alcohol Rehabilitation
Biomed Chromatogr. 2012 Jun; 26(6): 749-53
Hong Z, Cai G, Ma W, Wen J, Chai Y, Fan G
A rapid high-performance liquid chromatographic method was developed and validated for determination of tetrahydropalmatine (THP), an active component of Rhizoma Corydalis, in rat plasma. The samples were prepared using protein precipitation and separated on an Agilent XDB-C(18) column (150 × 4.6 mm, 5 µm) with the mobile phase consisting of methanol–0.1% phosphate acid solution, adjusted with triethylamine to pH 5.5 (65:35). Good linearity was found within 0.10–10.00 µg/mL of THP in rat plasma sample. The intra- and inter-day precision values were less than 10%. The developed method was successfully applied to assess the pharmacokinetics of THP in spontaneously hypertensive rats (SHR) and normotensive rats. After oral administration of a single dose of THP (60 mg/kg), the maximum plasma concentrations were 6.15 ± 2.1 and 7.54 ± 2.9 µg/mL for normotensive rats and SHR, respectively. The mean values of AUC(0–?) of THP in SHR were 81.44 ± 45.0 µg?h/mL, significantly higher (p < 0.05) than in normotensive rats (44.06 ± 19.6 µg?h/mL). The t(1/2) and MRT in SHR were much longer than that in healthy Sprague–Dawley rats, indicating slow elimination of THP in SHR. The results indicated that there are some differences in pharmacokinetics of THP in SHR and Sprague–Dawley rats and it is very important to investigate the pharmacokinetic properties of drugs in pathological conditions. HubMed – drug
Find More Drug And Alcohol Rehabilitation Information…